Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Nov;66(11):e27954.
doi: 10.1002/pbc.27954. Epub 2019 Aug 9.

Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi

Tisungane Mvalo  1   2 , Hillary M Topazian  1   3 , Portia Kamthunzi  1   4 , Jane S Chen  1   3 , Isobel Kambalame  1 , Pilirani Mafunga  1 , Noel Mumba  1 , Msandeni Chiume  5 , Khadija Paseli  5 , Gerald Tegha  1 , Wiza Kumwenda  1 , J Brett Heimlich  1 , Graham Ellis  1 , Nigel Key  6 , Satish Gopal  1   3   4   6 , Irving Hoffman  1   4 , Kenneth I Ataga  7 , Kate D Westmoreland  1   8
Affiliations
Observational Study

Real-world experience using hydroxyurea in children with sickle cell disease in Lilongwe, Malawi

Tisungane Mvalo et al. Pediatr Blood Cancer. 2019 Nov.

Abstract

Introduction: Sickle cell disease (SCD) is among the most common inherited hematologic diseases in sub-Saharan Africa (SSA). Historically, hydroxyurea administration in SSA has been restricted due to limited region-specific evidence for safety and efficacy.

Methods: We conducted a prospective observational cohort study of pediatric patients with SCD in Malawi. From January 2015 to November 2017, hydroxyurea at doses of 10-20 mg/kg/day was administered to children with clinically severe disease (targeted use policy). From December 2017 to July 2018, hydroxyurea was prescribed to all patients (universal use policy).

Results: Of 187 patients with SCD, seven (3.7%) died and 23 (12.3%) were lost to follow-up. The majority (135, 72.2%) were prescribed hydroxyurea, 59 (43.7%) under the targeted use policy and 76 (56.3%) under the universal use policy. There were no documented severe toxicities. Under the targeted use policy, children with SCD demonstrated absolute decreases in the rates of hospitalization (-4.1 per 1000 person-days; -7.2, -1.0; P = .004), fevers (-4.2 per 1000 person-days; -7.2, -1.1; P = .002), transfusions (-2.3 per 1000 person-days; 95% confidence interval: -4.9, 0.3; P = .06), and annual school absenteeism (-51.2 per person-year; -60.1, -42.3; P < .0001) within 6 months of hydroxyurea commencement.

Conclusion: We successfully implemented universal administration of hydroxyurea to children with SCD at a tertiary hospital in Malawi. Similar to recently reported trials, hydroxyurea was safe and effective during routine programmatic experience, with clinical benefits particularly among high-risk children. This highlights the importance of continued widespread scale-up of hydroxyurea within SCD programs across SSA.

Keywords: Malawi; hydroxyurea; pediatric; sickle cell disease; sub-Saharan Africa; treatment.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Statement

None of the authors have any have conflicts of interest to disclose.

Figures

Figure 1.
Figure 1.
Cumulative count of actively followed children with sickle cell disease at Kamuzu Central Hospital in Malawi from 2015 to 2018. Lighters bars represent all children (N=187), darker bars represent children on hydroxyurea (N = 135).
See this image and copyright information in PMC

References

    1. Jain DL, Apte M, Colah R, et al. Efficacy of Fixed Low Dose Hydroxyurea in Indian Children with Sickle Cell Anemia: A Single Center Experience. Indian Pediatr 2013;5:929–933. doi:10.1007/s13312-013-0264-0. - DOI - PubMed
    1. Piel FB, Patil AP, Howes RE, et al. Global epidemiology of Sickle haemoglobin in neonates: A contemporary geostatistical model-based map and population estimates. Lancet 2013;381(9861):142–151. doi:10.1016/S0140-6736(12)61229-X - DOI - PMC - PubMed
    1. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: A multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377(9778):1663–1672. doi:10.1016/S0140-6736(11)60355-3 - DOI - PMC - PubMed
    1. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: The HUSOFT extension study. Blood 2005;106(7):2269–2275. doi:10.1182/blood-2004-12-4973 - DOI - PMC - PubMed
    1. Grosse SD, Odame I, Atrash HK, Amendah DD, Piel FB, Williams TN. Sickle cell disease in Africa: A neglected cause of early childhood mortality. Am J Prev Med 2011;41(6 SUPPL.4):S398–S405. doi:10.1016/j.amepre.2011.09.013 - DOI - PMC - PubMed

Publication types

MeSH terms